{"id":"W2613863892","doi":"10.1177/1756287217702797","title":"Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies","year":2017,"lang":"en","type":"article","venue":"Therapeutic Advances in Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Astellas Pharma Global Development; Astellas Pharma Europe; European Association of Urology","keywords":"Mirabegron; Solifenacin; Tolterodine; Overactive bladder; Medicine; Urination; Urology; Placebo; Adverse effect; Lower urinary tract symptoms; Urinary incontinence; Internal medicine; Urinary system; Prostate","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002484341,0.0001350362,0.0007396664,0.0003123573,0.00006439178,0.000003556842,0.0001158178,0.00006437321,0.00007260909],"category_scores_gemma":[0.0001890924,0.0001003888,0.00004037406,0.0002059051,0.00107504,0.000191624,0.00008552174,0.0002352082,5.196815e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002878016,"about_ca_system_score_gemma":0.00004555671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005882854,"about_ca_topic_score_gemma":0.0001609421,"domain_scores_codex":[0.9987556,0.000155648,0.000336156,0.0002836581,0.0002010507,0.0002678593],"domain_scores_gemma":[0.9983707,0.0009277015,0.0001517155,0.0003461154,0.0001531357,0.00005060795],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1096004,0.004337352,0.7656659,0.0002933809,0.003664283,0.000143417,0.009709165,0.0003074785,0.0007802547,0.0005558555,0.000003037516,0.1049395],"study_design_scores_gemma":[0.0262315,0.008207033,0.9599481,0.00008194488,0.001264361,0.00001148276,0.001220331,0.0009547856,0.0002769057,0.00104828,0.0005884464,0.0001668012],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882975,0.009885179,0.0001268912,0.0004459612,0.00002693771,0.0004202091,0.00003378646,0.000003638445,0.0007599205],"genre_scores_gemma":[0.9953518,0.004306185,0.0001697984,0.00008354014,0.00000917308,0.00001939977,0.00001350619,0.000009186224,0.00003744289],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1942822,"threshold_uncertainty_score":0.4093737,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03120800412144471,"score_gpt":0.4128818922531041,"score_spread":0.3816738881316594,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}